Abcam, ab257580, Human PFKP knockout HeLa cell lysate

Size: 1Kit
PFKP KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon3.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon3.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-PFKP, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PFKP also known as 6-phosphofructokinase platelet type functions as an important glycolytic enzyme that catalyzes the phosphorylation of fructose 6-phosphate to fructose 16-bisphosphate using ATP. This process shows the rate-limiting step in glycolysis. The PFKP protein weighs approximately 85 kDa. Expression occurs in various tissues with high presence in platelets and muscle tissues indicating its significant role in energy metabolism.
Biological function summary
PFKP plays an essential role in maintaining energy supply ensuring efficient glycolysis during high energy demands. It associates with other isoforms PFKM (muscle) and PFKL (liver) to form a tetrameric complex which can adapt its activity based on the energy needs of the cell. This adaptability defines its contribution to cellular metabolism regulation considering energy substrates and signaling molecules.
Pathways
The function of PFKP ties closely to glycolysis and the larger metabolic pathways managing energy production such as the tricarboxylic acid (TCA) cycle. Within these pathways PFKP interacts with other metabolic regulators including AMP-activated protein kinase (AMPK) which influences cell metabolism in response to energy availability. Connections with PFKL and PFKM reveal that PFKP's activity relates to the overall glycolytic flux and energy balance.
PFKP's alterations contribute to metabolic conditions like cancer and diabetes. Its dysregulation in cancer cells supports the Warburg effect where tumor cells prefer glycolysis. The link with metabolic proteins such as AMPK also indicates a potential role in diabetes as both disorders involve shifts in energy metabolism. Understanding PFKP's impact on these diseases helps in developing therapeutic strategies targeting metabolic pathways.